NDAOPHTHALMICSOLUTION/DROPS1 Generic Approved
Approved
Apr 1998
Lifecycle
LOE Approaching
Competitive Pressure
45/100
Clinical Trials
13
Data completeness
4/8 — Partial
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COSOPT is a fixed-dose combination ophthalmic solution containing dorzolamide hydrochloride (carbonic anhydrase inhibitor) and timolol maleate (non-selective beta-blocker) for twice-daily topical administration. It reduces elevated intraocular pressure by decreasing aqueous humor secretion through dual mechanisms. The combination treats open-angle glaucoma and ocular hypertension in patients seeking convenient once-daily dosing compared to separate agents.
$0.135MPart D
LOE ApproachingDeclining
Product faces imminent loss of exclusivity with only $135K in Part D spending, indicating a small and contracting commercial footprint requiring optimization or transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (13)
Comparison of Intraocular Pressure (IOP)-Lowering Efficacy and Safety of AZORGA® Ophthalmic Suspension and COSOPT® Ophthalmic Solution
Started Dec 2014
218 enrolled
Open-Angle GlaucomaOcular Hypertension
Patient Preference Comparison of AZARGA Versus COSOPT
Started Sep 2011
112 enrolled
Open-Angle GlaucomaOcular Hypertension
Patient Preference Comparison of AZARGA Versus COSOPT in Patients With Glaucoma
Started Sep 2010
120 enrolled
Glaucoma
Comparison of the Efficacy of AZARGA® Versus COSOPT® in Patients With Open-Angled Glaucoma or Ocular Hypertension
Started Apr 2010
70 enrolled
GlaucomaOcular Hypertension
The DIOXXACT Trial(Diurnal IOP and OBF Xalatan vs Xalatan And Cosopt Trial)
Started May 2009
25 enrolled
Eye Disease
Worked on COSOPT at Thea Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.